Corrigendum: “Comparative Effectiveness of Bimekizumab in Psoriatic Arthritis: A Model‐Based Meta‐Analysis of American College of Rheumatology Response Criteria”

Documenti analoghi

• Model‐Informed Drug Development‐Based Bridging from Subcutaneous to Intravenous Secukinumab Dosing: Approval in Psoriatic Arthritis and Axial Spondyloarthritis
  di: Thomas Dumortier, et al.
  Pubblicazione: (2025)
• Model‐Informed Drug Development‐Based Approval of Intravenous Secukinumab for the Treatment of Adult Patients with Active Psoriatic Arthritis, Active Ankylosing Spondylitis, and Active Non‐Radiographic Axial Spondyloarthritis
  di: Dipak S. Pisal, et al.
  Pubblicazione: (2024)
• Risk of Malignancies and Major Adverse Cardiovascular Events Related to JAK Inhibitors in Rheumatoid Arthritis: A Meta‐Analysis
  di: Hongmei Duan, et al.
  Pubblicazione: (2025)
• Extrapolation of Upadacitinib Efficacy in Juvenile Idiopathic Arthritis Leveraging Pharmacokinetics, Exposure–Response Models, and Real‐World Patient Data
  di: Yuli Qian, et al.
  Pubblicazione: (2024)
• Partial Residual Plots as an Integrated Model Diagnostic Tool in Model‐Based Meta‐Analysis
  di: John Maringwa, et al.
  Pubblicazione: (2024)